Ocular Therapeutix Inc [OCUL] stock is trading at $9.89, down -1.69%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The OCUL shares have gain 16.08% over the last week, with a monthly amount drifted -10.74%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, TD Cowen upgraded its rating to Buy on June 20, 2024, and elevated its price target to $11. BofA Securities started tracking the stock assigning a Buy rating and suggested a price target of $15 on February 09, 2024. Robert W. Baird initiated its recommendation with a Outperform and recommended $18 as its price target on April 21, 2023. In a note dated August 10, 2021, H.C. Wainwright upgraded an Buy rating on this stock but restated the target price of $17.
Ocular Therapeutix Inc [OCUL] stock has fluctuated between $2.16 and $11.77 over the past year. Currently, Wall Street analysts expect the stock to reach $17.5 within the next 12 months. Ocular Therapeutix Inc [NASDAQ: OCUL] shares were valued at $9.89 at the most recent close of the market. An investor can expect a potential return of 76.95% based on the average OCUL price forecast.
Analyzing the OCUL fundamentals
Ocular Therapeutix Inc [NASDAQ:OCUL] reported sales of 61.44M for the trailing twelve months, which represents a growth of 2.28%. Gross Profit Margin for this corporation currently stands at 0.91% with Operating Profit Margin at -2.3%, Pretax Profit Margin comes in at -2.84%, and Net Profit Margin reading is -2.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.36, Equity is -0.57 and Total Capital is -0.31. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 9.71 points at the first support level, and at 9.52 for the second support level. However, for the 1st resistance point, the stock is sitting at 10.11, and for the 2nd resistance point, it is at 10.33.
Ratios To Look Out For
For context, Ocular Therapeutix Inc’s Current Ratio is 13.01. Further, the Quick Ratio stands at 12.94, while the Cash Ratio is 11.75. Considering the valuation of this stock, the price to sales ratio is 24.88, the price to book ratio is 4.40.
Transactions by insiders
Recent insider trading involved Heier Jeffrey S., Chief Scientific Officer, that happened on Nov 25 ’24 when 2948.0 shares were sold. Chief Development Officer, Kaiser Peter completed a deal on Nov 25 ’24 to sell 2897.0 shares. Meanwhile, Chief Strategy Officer Nayak Sanjay sold 1814.0 shares on Nov 25 ’24.
